FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:1131-1132 March 17, 2005 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Solomon, S. D. Related Article by Nussmeier, N. A. Related Article by Bresalier, R. S. PubMed Citation

This issue of the Journal contains three articles about the adverse cardiovascular effects of agents that selectively inhibit one form of prostaglandin endoperoxide synthase, commonly known as cyclooxygenase-2 (COX-2).^1,2,3 This is part of a long bench-to-bedside story with an adverse outcome that was not widely anticipated at its start. Unfortunately, as the evidence began to suggest unexpected toxicity of this group of agents, the same zeal that had driven the clinical investigation to show their gastrointestinal safety was not evidenced by studies designed to show their cardiovascular safety.

In 1987, evidence emerged⁴ that there were probably two enzymes — cyclooxygenase-1 . . . [Full Text of this Article]

Source Information

This article was published at www.nejm.org on February 15, 2005.

Related Letters:

Cardiovascular Risk Associated with Celecoxib
Brophy J. M., Solomon S. D., Wittes J., McMurray J., the APC Study Cardiovascular Safety Committee and Investigators , Psaty B. M., Furberg C. D.
Extract | Full Text | PDF  
N Engl J Med 2005; 352:2648-2650, Jun 23, 2005. Correspondence

This article has been cited by other articles:

• Szekely, C. A., Green, R. C., Breitner, J.C.S., Ostbye, T., Beiser, A. S., Corrada, M. M., Dodge, H. H., Ganguli, M., Kawas, C. H., Kuller, L. H., Psaty, B. M., Resnick, S. M., Wolf, P. A., Zonderman, A. B., Welsh-Bohmer, K. A., Zandi, P. P. (2008). No advantage of A{beta}42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology 70: 2291-2298 [Abstract] [Full Text]  
• Arehart, E., Stitham, J., Asselbergs, F. W., Douville, K., MacKenzie, T., Fetalvero, K. M., Gleim, S., Kasza, Z., Rao, Y., Martel, L., Segel, S., Robb, J., Kaplan, A., Simons, M., Powell, R. J., Moore, J. H., Rimm, E. B., Martin, K. A., Hwa, J. (2008). Acceleration of Cardiovascular Disease by a Dysfunctional Prostacyclin Receptor Mutation: Potential Implications for Cyclooxygenase-2 Inhibition. Circ. Res. 102: 986-993 [Abstract] [Full Text]  
• Salinas, G., Rangasetty, U. C., Uretsky, B. F., Birnbaum, Y. (2007). The Cycloxygenase 2 (COX-2) Story: It's Time to Explain, Not Inflame. J CARDIOVASC PHARMACOL THER 12: 98-111 [Abstract]  
• Bennett, C. L., Nebeker, J. R., Yarnold, P. R., Tigue, C. C., Dorr, D. A., McKoy, J. M., Edwards, B. J., Hurdle, J. F., West, D. P., Lau, D. T., Angelotta, C., Weitzman, S. A., Belknap, S. M., Djulbegovic, B., Tallman, M. S., Kuzel, T. M., Benson, A. B., Evens, A., Trifilio, S. M., Courtney, D. M., Raisch, D. W. (2007). Evaluation of Serious Adverse Drug Reactions: A Proactive Pharmacovigilance Program (RADAR) vs Safety Activities Conducted by the Food and Drug Administration and Pharmaceutical Manufacturers. Arch Intern Med 167: 1041-1049 [Abstract] [Full Text]  
• Pyrko, P., Kardosh, A., Liu, Y.-T., Soriano, N., Xiong, W., Chow, R. H., Uddin, J., Petasis, N. A., Mircheff, A. K., Farley, R. A., Louie, S. G., Chen, T. C., Schonthal, A. H. (2007). Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib. Molecular Cancer Therapeutics 6: 1262-1275 [Abstract] [Full Text]  
• Stewart, W. F., Shah, N. R., Selna, M. J., Paulus, R. A., Walker, J. M. (2007). Bridging The Inferential Gap: The Electronic Health Record And Clinical Evidence. Health Aff (Millwood) 26: w181-w191 [Abstract] [Full Text]  
• Zarraga, I. G. E., Schwarz, E. R. (2007). Coxibs and Heart Disease: What We Have Learned and What Else We Need to Know. J Am Coll Cardiol 49: 1-14 [Abstract] [Full Text]  
• D'Souza, A L (2007). Ageing and the gut. Postgrad. Med. J. 83: 44-53 [Abstract] [Full Text]  
• Stafford-Smith, M. (2006). Hurry up and slow down: Lessons in drug development from the COX-2 inhibitors/Se hater et ralentir: les lecons a tirer de la production des inhibiteurs de la COX-2.. Canadian J. Anesthesia 53: 973-977 [Full Text]  
• Hur, C., Chan, A. T, Tramontano, A. C, Gazelle, G S. (2006). Coxibs Versus Combination NSAID and PPI Therapy for Chronic Pain: An Exploration of the Risks, Benefits, and Costs. The Annals of Pharmacotherapy 40: 1052-1063 [Abstract] [Full Text]  
• Askling, J, Fored, C M, Geborek, P, Jacobsson, L T H, van Vollenhoven, R, Feltelius, N, Lindblad, S, Klareskog, L (2006). Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 65: 707-712 [Abstract] [Full Text]  
• Lustberg, M. E., Gelber, A. C., Becker, M. A., Palo, W. A., Joseph-Ridge, N. (2006). Febuxostat versus allopurinol for gout.. NEJM 354: 1532-1533 [Full Text]  
• Sooriakumaran, P (2006). COX-2 inhibitors and the heart: are all coxibs the same?. Postgrad. Med. J. 82: 242-245 [Abstract] [Full Text]  
• Caldwell, B., Aldington, S., Weatherall, M., Shirtcliffe, P., Beasley, R. (2006). Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis.. JRSM 99: 132-140 [Abstract] [Full Text]  
• Deyle, G. D, Allison, S. C, Matekel, R. L, Ryder, M. G, Stang, J. M, Gohdes, D. D, Hutton, J. P, Henderson, N. E, Garber, M. B (2005). Physical Therapy Treatment Effectiveness for Osteoarthritis of the Knee: A Randomized Comparison of Supervised Clinical Exercise and Manual Therapy Procedures Versus a Home Exercise Program. ptjournal 85: 1301-1317 [Abstract] [Full Text]  
• Berenson, R. A. (2005). Which Way For Competition? None Of The Above. Health Aff (Millwood) 24: 1536-1542 [Abstract] [Full Text]  
• Olson, D. M. (2005). The Promise of Prostaglandins: Have They Fulfilled Their Potential as Therapeutic Targets for the Delay of Preterm Birth?. Reproductive Sciences 12: 466-478 [Abstract]  
• Caporali, R, Montecucco, C (2005). Cardiovascular effects of coxibs. Lupus 14: 785-788 [Abstract]  
• Waller, P. C, Evans, S. J W, Beard, K. (2005). Drug safety and regulation. BMJ 331: 4-5 [Full Text]  
• Brophy, J. M., Solomon, S. D., Wittes, J., McMurray, J., the APC Study Cardiovascular Safety Committee and, , Psaty, B. M., Furberg, C. D. (2005). Cardiovascular Risk Associated with Celecoxib. NEJM 352: 2648-2650 [Full Text]  
• Bennett, C. L., Nebeker, J. R., Lyons, E. A., Samore, M. H., Feldman, M. D., McKoy, J. M., Carson, K. R., Belknap, S. M., Trifilio, S. M., Schumock, G. T., Yarnold, P. R., Davidson, C. J., Evens, A. M., Kuzel, T. M., Parada, J. P., Cournoyer, D., West, D. P., Sartor, O., Tallman, M. S., Raisch, D. W. (2005). The Research on Adverse Drug Events and Reports (RADAR) Project. JAMA 293: 2131-2140 [Abstract] [Full Text]  
• Tondini, C., Labianca, R. (2005). Tailoring a tailored treatment: the importance of fine-tuning on the patient. Ann Oncol 16: 683-685 [Full Text]  
• Goldfarb, B. (2005). FDA Panel Recommends COX-2 Drugs Remain on Market. DOC News 2: 1-8 [Full Text]